[
  {
    "disease_name": "NASH",
    "market_size_billions": 8.2,
    "growth_rate_percent": 48,
    "approved_drugs_count": 2,
    "top_competitors": ["Resmetirom", "Rezdiffra"],
    "market_maturity": "Emerging",
    "unmet_need": "High"
  },
  {
    "disease_name": "Alzheimer's Disease",
    "market_size_billions": 9.8,
    "growth_rate_percent": 6.5,
    "approved_drugs_count": 7
  },
  {
    "disease_name": "Colorectal Cancer Prevention",
    "market_size_billions": 4.3,
    "growth_rate_percent": 5.2,
    "approved_drugs_count": 12
  },
  {
    "disease_name": "Nonalcoholic Fatty Liver Disease",
    "market_size_billions": 2.7,
    "growth_rate_percent": 10.1,
    "approved_drugs_count": 3
  },
  {
    "disease_name": "Multiple Sclerosis",
    "market_size_billions": 22.5,
    "growth_rate_percent": 4.7,
    "approved_drugs_count": 15
  },
  {
    "disease_name": "Diabetic Nephropathy",
    "market_size_billions": 6.4,
    "growth_rate_percent": 7.8,
    "approved_drugs_count": 5
  },
  {
    "disease_name": "Heart Failure with Preserved Ejection Fraction",
    "market_size_billions": 8.9,
    "growth_rate_percent": 8.3,
    "approved_drugs_count": 9
  },
  {
    "disease_name": "Migraine Prophylaxis",
    "market_size_billions": 5.6,
    "growth_rate_percent": 5.0,
    "approved_drugs_count": 10
  },
  {
    "disease_name": "Type 1 Diabetes",
    "market_size_billions": 14.1,
    "growth_rate_percent": 6.1,
    "approved_drugs_count": 11
  },
  {
    "disease_name": "Cancer-Associated Thrombosis",
    "market_size_billions": 3.8,
    "growth_rate_percent": 9.2,
    "approved_drugs_count": 4
  },
  {
    "disease_name": "Osteoarthritis",
    "market_size_billions": 11.7,
    "growth_rate_percent": 4.3,
    "approved_drugs_count": 13
  }
]
